Get started
Lexeo Therapeutics, Inc.Lexeo Therapeutics, Inc.Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

LXEO chart


Full chart

LXEO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪213.94 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.84 USD
Net income (FY)
‪−66.39 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪23.82 M‬
Beta (1Y)
1.73

Employees


Employees (FY)
58
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.14 M‬ USD

About Lexeo Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
R. Nolan Townsend
Website
lexeotx.com
Headquarters
New York
Founded
2017
FIGI
BBG00YB1C8M5
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

LXEO news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of LXEO is 6.47 USD — it has increased by 4.35% in the past 24 hours. Watch Lexeo Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lexeo Therapeutics, Inc. stocks are traded under the ticker LXEO.
LXEO stock has fallen by −17.58% compared to the previous week, the month change is a −35.43% fall, over the last year Lexeo Therapeutics, Inc. has showed a −40.31% decrease.
We've gathered analysts' opinions on Lexeo Therapeutics, Inc. future price: according to them, LXEO price has a max estimate of 28.00 USD and a min estimate of 16.00 USD. Watch LXEO chart and read a more detailed Lexeo Therapeutics, Inc. stock forecast: see what analysts think of Lexeo Therapeutics, Inc. and suggest that you do with its stocks.
LXEO reached its all-time high on Jan 18, 2024 with the price of 22.33 USD, and its all-time low was 5.77 USD and was reached on Nov 20, 2024. View more price dynamics on LXEO chart.
See other stocks reaching their highest and lowest prices.
LXEO stock is 8.39% volatile and has beta coefficient of 1.73. Track Lexeo Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Lexeo Therapeutics, Inc. there?
Today Lexeo Therapeutics, Inc. has the market capitalization of ‪213.91 M‬, it has decreased by −6.77% over the last week.
Yes, you can track Lexeo Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Lexeo Therapeutics, Inc. is going to release the next earnings report on Mar 17, 2025. Keep track of upcoming events with our Earnings Calendar.
LXEO earnings for the last quarter are −0.89 USD per share, whereas the estimation was −0.68 USD resulting in a −31.19% surprise. The estimated earnings for the next quarter are −0.81 USD per share. See more details about Lexeo Therapeutics, Inc. earnings.
Lexeo Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
LXEO net income for the last quarter is ‪−29.49 M‬ USD, while the quarter before that showed ‪−21.24 M‬ USD of net income which accounts for −38.85% change. Track more Lexeo Therapeutics, Inc. financial stats to get the full picture.
No, LXEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 58.00 employees. See our rating of the largest employees — is Lexeo Therapeutics, Inc. on this list?
Like other stocks, LXEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lexeo Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lexeo Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lexeo Therapeutics, Inc. stock shows the strong sell signal. See more of Lexeo Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.